NASDAQ:PHIO Phio Pharmaceuticals Q1 2026 Earnings Report $1.09 -0.04 (-3.54%) As of 02:14 PM Eastern ProfileEarnings HistoryForecast Phio Pharmaceuticals EPS ResultsActual EPS-$0.34Consensus EPS -$0.24Beat/MissMissed by -$0.10One Year Ago EPSN/APhio Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APhio Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time7:00AM ETUpcoming EarningsPhio Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Phio Pharmaceuticals Earnings HeadlinesHC Wainwright Issues Pessimistic Outlook for PHIO EarningsAugust 30 at 1:13 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Phio Pharmaceuticals (NASDAQ:PHIO)August 28 at 1:12 AM | americanbankingnews.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.August 31 at 1:00 AM | The Oxford Club (Ad)Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finanznachrichten.dePhio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finance.yahoo.comPhio Pharmaceuticals expands global patent portfolio with new international patent milestonesJuly 15, 2026 | msn.comSee More Phio Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phio Pharmaceuticals and other key companies, straight to your email. Email Address About Phio PharmaceuticalsPhio Pharmaceuticals (NASDAQ:PHIO), Inc. (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology. Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion. The lead programs in its pipeline include PH‐762, being evaluated in collaboration with Janssen for solid tumor indications, and PH‐687, an internally developed candidate with potential in immuno‐oncology. Both candidates are currently in preclinical or early clinical testing, as the company seeks to validate safety, tolerability and proof-of‐mechanism in human studies. In addition to its collaboration with Janssen, Phio has established partnerships with academic institutions and research organizations to explore the broader utility of TRiMTM in hard‐to‐treat cancers. The company’s R&D efforts are supported by preclinical data demonstrating potent gene knockdown and immune modulation, laying the groundwork for combination strategies with established immunotherapies. Founded in 2014 and headquartered in Newtown, Pennsylvania, Phio Pharmaceuticals operates primarily in the United States while engaging with global research networks. The company is led by President and Chief Executive Officer Seth Hewitt, whose background in translational oncology and RNAi drug development guides Phio’s strategic direction and clinical advancement efforts.View Phio Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The SaaSpocalypse Trade Is Cracking, and These 5 Stocks Are Leading HigherMarketBeat Week in Review – 08/24 - 08/28From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens3 Retail Stocks to Watch After a Big Consumer Earnings WeekRubrik’s AI Security Bet Could Power the Next Leg HigherPalo Alto’s Rally Has One Big Problem Ahead of EarningsDLocal Is Testing the Breakout Level That Could Change Its Stock Story Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
